Our mutational analysis found PIK3CA mutations in 12% of the patients, which is relatively lower than the results previous reported (13–36%;[2]), possibly due to difference in quality of samples for DNA extraction, as we used archival FFPE biopsy specimens from patients with mostly locally advanced cancers before treatment. The gene discussed is PIK3CA; the disease is cancer.